parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in myonuclei	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	9 Parkinson's papers of 1,851	0.70
pathways Reactome	7 pathways; mostly mitochondrial quality control	1.00

No case: the score is under the bar. Receipt 7289

receipt 7297: MEF2C in dopamine neurons, braak

power: full sample +0.06 (p 0.807, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.05 (p 0.840, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.715, n 18). could be the mix.
skeptic: leave-one-out range -0.02 to +0.22, sign flips 2; without severely affected donors +0.06 (p 0.807, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MEF2C in dopamine neurons.

case closed: nothing better to follow up.

receipt 7296: MEF2C in microglia, braak

power: full sample -0.08 (p 0.741, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.16 (p 0.538, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.05 (p 0.840, n 18). could be the mix.
skeptic: leave-one-out range -0.22 to +0.01, sign flips 2; without severely affected donors -0.08 (p 0.741, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MEF2C in microglia.

case closed: nothing better to follow up.

loading the receipts